ClinicalTrials.gg
TerminatedNCT06784947Updated Nov 20, 2026Results posted

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

A Phase 2 interventional study of Tiragolumab and Atezolizumab in Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, sponsored by University of Colorado, Denver. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know · 11 judgments · 3 readings being read again

Why this study was terminated
Drugs unavailable
Updated Nov 20, 2026Now TerminatedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Spinocerebellar Degenerations with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Spinocerebellar Degenerations · United States.

Enrollment
13th of 15
13 · median 48
Started
2025
the only one that year
Phase 2
7 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Spinocerebellar Degenerations with a site in United States, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, and was the 17th registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

3 of the 18 studies in Spinocerebellar Degenerations with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Spinocerebellar Degenerations with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are:

  1. Does the study treatment effectively treat colorectal cancer?
  2. Is the study treatment safe for patients with colorectal cancer?
  3. How does the study treatment effect the immune system in patients with colorectal cancer?

Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.

Read the detailed description

This is a phase II study investigating the efficacy and safety of a triple-combination immunotherapy regimen in patients diagnosed with microsatellite stable metastatic colorectal cancer (MSS mCRC), refractory to fluorouracil, oxaliplatin, and irinotecan chemotherapy. The trial is designed as a single-arm, Simon two-stage study.

All participants will receive a fixed-dose regimen of the three agents: atezolizumab (1200 mg), bevacizumab (15 mg/kg), and tiragolumab (600 mg), administered intravenously on day 1 of 21-day cycles. Treatment response will be assessed by imaging using RECIST v1.1 every 9 weeks. Study treatment will be continued until disease progression, unacceptable toxicity, death, decision by the patient and/or treating physician to withdraw from the study, pregnancy, or study termination, whichever occurs first.

This study will enroll patients in 2 cohorts: A and B. Patients in Cohort A will undergo pre-treatment and on-treatment tumor biopsies for correlative studies. Patient in Cohort B will not receive study biopsies. Patients in Cohorts A and B will otherwise receive identical treatment.

03

Conditions studied

  • Microsatellite Stable (MSS) Colorectal Cancer (CRC)
  • Metastatic Colorectal Cancer (CRC)
  • Colorectal Cancer Stage IV

Keywords

  • immunotherapy
  • microsatellite stable colorectal cancer
  • tiragolumab
  • metastatic colorectal cancer
  • atezolizumab
  • bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to sign the consent form.
  2. Stated willingness and ability to comply with all study procedures and be available for the duration of the study.
  3. ≥ 18 years at the time of .
  4. confirmed, unresectable, colorectal adenocarcinoma.
  5. (disease that can be viewed and measured on scans), as assessed by the investigator per v1.1.
  6. If in Cohort A, (1) the patient must state willingness to undergo pre- and on-treatment biopsies, and (2) the patient's disease must be amenable to biopsy.
  7. performance status of 0-2.
  8. Documented microsatellite stable and/or proficient mismatch repair status.
  9. Documented testing for KRAS, NRAS, and BRAF mutation status.
  10. Progression on or intolerance to prior therapy for unresectable, metastatic CRC including at least (1) fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy AND (2) EGFR inhibitor therapy for patients with KRAS/NRAS/BRAF wild-type, left-sided disease.
  11. Adequate hematologic and end organ function, defined by laboratory results obtained within 28 days prior to the first dose of study treatment.

    • ≥ 1.2 × 10\^9/L
    • Lymphocyte count ≥ 0.5 x 10\^9/L
    • count ≥ 100 × 10\^9/L, without transfusion in the prior week.
    • ≥ 9 g/dL; patients may be transfused to meet this criterion.
    • Serum total ≤ 1.5 x the (ULN); patients with known Gilbert's disease may have a bilirubin ≤ 3.0 × ULN.
    • , alanine transaminase, and alkaline phosphatase ≤ 2.5 × ULN with the following exceptions:

      • For patients with documented liver metastases, AST and/or ALT ≤ 5 × ULN.
      • For patients with documented liver or bone metastases, ALP ≤ 5 × ULN.
    • Serum albumin ≥ 25 g/L (2.5 g/dL)
    • ≥ 45 mL/min as calculated using the Cockcroft-Gault formula or measured using a 24-hour urine collection.
    • For patients not receiving therapeutic anticoagulation, and activated partial thromboplastin time ≤ 1.5 × ULN.
  12. Patients receiving therapeutic anticoagulation must be on a stable regimen, with INR and aPTT within the expected therapeutic range of intended use of the anticoagulant.
  13. Negative testing at screening, or, for those with known history of HIV, documented control of infection on anti-retroviral therapy with evidence of undetectable viral load and of >500 cells/microL for a least 6 months prior to enrollment.
  14. Negative surface antigen (HBsAg) test at screening.
  15. Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb test at screening accompanied by either of the following:

    • Negative total hepatitis B core antibody (HBcAb)
    • Positive total HBcAb test followed by quantitative hepatitis B virus (HBV) DNA \< 500 IU/mL.
  16. Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening.
  17. For women of (WOCBP): agreement to refrain from heterosexual intercourse or use .
  18. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  1. Illness or condition that may interfere with a patient's capacity to understand, follow, and/or comply with study procedures.
  2. Known microsatellite instability-high or deficient mismatch repair status, or unknown status for both MSI and MMR.
  3. Prior testing documenting a BRAF V600E mutation, or unknown testing results for KRAS, NRAS, and BRAF.
  4. A limited number of patients with active liver will be permitted in this trial. Those with a history of definitively treated liver metastases with treatment occurring at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging may be eligible to enroll as a patient without active liver disease.
  5. Known symptomatic, untreated, or actively progressing central nervous system metastases. Asymptomatic patients with treated CNS lesions are eligible, provided that additional criteria are met.
  6. History of or carcinomatous meningitis.
  7. Spinal cord compression not definitively treated with surgery and/or radiation.
  8. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.
  9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
  10. History of other than colorectal cancer within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.
  11. Active disease, history of autoimmune disease requiring treatment with , disease modifying agents, and/or therapy, or immune deficiency including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the exceptions listed below:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for the study provided all of following conditions are met:

      • Rash must cover \< 10% of body surface area.
      • Disease is well controlled at baseline \& requires only low-potency topical corticosteroids.
      • There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.
  12. Prior allogeneic stem cell or solid organ transplantation.
  13. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  14. Known history of tuberculosis and/or active tuberculosis.
  15. Active bowel inflammation on imaging at the time of enrollment.
  16. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  17. Clinical signs or symptoms of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.
  18. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
  19. History of or active cardiovascular dysfunction, including the following:

    • History of stroke or within 6 months prior to first dose of study treatment.
    • History of myocardial infarction within 6 months prior to first dose of study treatment.
    • Heart failure with Class II or higher symptoms within 3 months prior to initiation of study treatment.
    • Unstable arrhythmia.
    • Coronary heart disease that is symptomatic or unstable angina.
  20. Inadequately controlled hypertension. Anti-hypertensive therapy to achieve these parameters is allowed.
  21. History of hypertensive crisis or hypertensive encephalopathy.
  22. Grade ≥ 2 proteinuria, as demonstrated by ≥ 2+ protein on dipstick urinalysis and ≥ 1.0 g of protein in a 24-hour urine collection.

    o All patients with ≥ 2+ protein on dipstick urinalysis at screening must undergo a 24-hour urine collection for protein. Patients with \< 2+ protein on dipstick urinalysis are eligible for the study and do not require 24-hour urine collection.

  23. Significant vascular disease within 6 months prior to initiation of study treatment.
  24. History of Grade 4 venous thromboembolism.
  25. History of Grade ≥ 2 hemoptysis, or other serious hemorrhage or bleeding risk, within 1 month prior to screening.
  26. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding.
  27. Major surgical procedure, or significant traumatic injury, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study.

    o Study-related are not considered major surgical procedures in this study.

  28. Minor surgical procedures, including placement of a vascular access device, within 7 days prior to initiation of study treatment, with the following exceptions:

    • Study-related biopsies are NOT considered as surgical procedures under the exclusion criteria. Pre-treatment study biopsies should be performed at least 3 days prior to study treatment initiation.
    • Patients must have sufficiently recovered from any prior surgery, including adequate wound healing.
  29. Serious, non-healing wound, active ulcer, or untreated bone fracture.
  30. Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety.
  31. Positive Epstein-Barr virus (EBV) viral capsid antigen immunoglobulin M (IgM) test at screening. An EBV polymerase chain reaction (PCR) test should be performed as clinically indicated to screen for acute infection or suspected chronic active infection. Patients with a positive EBV PCR test are excluded.
  32. Current or recent (\< 10 days prior to initiation of study treatment) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day), or recent (\< 21 days prior to initiation of study treatment) use of therapeutic thrombolytic agents.
  33. Recent (\< 21 days prior to initiation of study treatment) initiation of full-dose oral or parenteral anticoagulants. The use of full-dose oral or parenteral anticoagulants is permitted as long as the following criteria are met:

    • The and/or aPTT are within therapeutic limits (according to the medical standard of the enrolling institution).
    • The patient has been on a stable dose of anticoagulants for at least 21 days prior to initiation of study therapy.
    • There is no evidence of or clinical concern for new or worsening thromboembolism within 21 days prior to initiation of study treatment.
    • The patient has no history of serious hemorrhage or bleeding risk.
    • The patient has no persisting bleeding diathesis or anatomic or pathologic condition that significantly increases the risk of hemorrhage.
  34. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment.

    o Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation) are eligible for the study.

  35. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment, within 90 days after the final dose of tiragolumab, or within 5 months after the final dose of atezolizumab.
  36. Current treatment with anti-viral therapy for .
  37. Treatment with any systemic anti-cancer therapy within 21 days or 5 half-lives of starting study treatment, whichever is shorter.
  38. Treatment with an therapy within 42 days of initiation of study treatment.
  39. Prior treatment with CD137 agonists or investigational immune checkpoint blockade therapies, including anti-LAG3, , anti-PD-1, anti-PD-L1, or anti-TIGIT agents.
  40. Prior radiation therapy within 14 days of Cycle 1, Day 1 of study treatment, and/or persistence of radiation-related adverse effects. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis prior to study treatment start. Palliative radiation therapy (as long as it does not involve target lesions) is permitted on the study.
  41. Treatment with systemic immunostimulatory agents, including, but not limited to, interferon and IL-2, within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment.
  42. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-α [TNF- α] agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

    • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.
    • Patients who received mineralocorticoids, corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
    • Patients requiring chronic use of ≥ 10 mg prednisone per day or equivalent
  43. Requirement for treatment with any medicinal product that contraindicates the use of any of the study treatments, may interfere with the planned treatment, impact patient compliance, or puts the patient at higher risk for treatment-related complications.
  44. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
  45. Known to Chinese hamster ovary cell products or to any component of the atezolizumab, bevacizumab, or tiragolumab formulations.
  46. Pregnancy or breastfeeding, or intention of becoming pregnant.
  47. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Treatment with or without Biopsy

    Participants receive combination therapy with atezolizumab, bevacizumab, and tiragolumab administered intravenously in 21-day cycles. All participants receive the same treatment regimen; assignment to Cohort A (with tumor biopsies) or Cohort B (no biopsies) does not affect treatment administration.

    Drug: Tiragolumab · Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.

  • Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

  • Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per RECIST v1.1

    Objective response rate (ORR) was defined as the proportion of patients whose best overall response was complete response (CR) or partial response (PR). Patients with stable disease (SD), progressive disease (PD), not evaluable (NE), or missing post-baseline response assessments were counted as non-responders.

    Time frame: From screening/baseline tumor assessment through the last available tumor assessment, up to 5 months.

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment. Per protocol, patients were followed until disease progression, death, withdrawal of consent, loss to follow-up, or study termination. Survival follow-up was conducted every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit. The study was terminated before participants reached the first prespecified survival follow-up assessment, scheduled 3 months after the Final Study/Treatment Discontinuation Visit.

    Time frame: From enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment

  2. Overall Survival (OS)

    Overall survival (OS) was defined as the time from enrollment to death from any cause. Patients without a documented death were censored at their off-study date. Per protocol, patients were followed until death, withdrawal of consent, loss to follow-up, or study termination. Survival follow-up was scheduled every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit. The study was terminated before participants reached the first prespecified survival follow-up assessment, scheduled 3 months after the Final Study/Treatment Discontinuation Visit.

    Time frame: From enrollment until death from any cause, withdrawal of consent, loss to follow-up, or study termination, with survival follow-up every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit, per protocol.

07

Results

Posted Nov 20, 2026
Limitations and caveats
This study was closed early due to the decision by Genentech to stop the development and manufacture of tiragolumab. This limited patient numbers; only 12 patients were enrolled and treated compared to 44 patients planned according to the protocol. Furthermore, patients were required to come off of treatment due to study discontinuation, limiting treatment and follow-up duration. As a result, secondary efficacy endpoints were not collected due to early closure.

Participant flow

Patients were recruited to participate at the University of Colorado Cancer Center from March 2025-August 2025. The study was closed early due to the decision by Genentech to stop the development of tiragolumab.

Participant flow — Overall Study
MilestoneTreatment With or Without Biopsy
Started12
Completed12
Not completed0

Outcome measures

PrimaryObjective Response Rate (ORR) Per RECIST v1.1

Objective response rate (ORR) was defined as the proportion of patients whose best overall response was complete response (CR) or partial response (PR). Patients with stable disease (SD), progressive disease (PD), not evaluable (NE), or missing post-baseline response assessments were counted as non-responders.

Time frame:
From screening/baseline tumor assessment through the last available tumor assessment, up to 5 months.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Per RECIST v1.1
ParticipantsTreatment With or Without Biopsy
Objective Response Rate (ORR) Per RECIST v1.13
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment. Per protocol, patients were followed until disease progression, death, withdrawal of consent, loss to follow-up, or study termination. Survival follow-up was conducted every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit. The study was terminated before participants reached the first prespecified survival follow-up assessment, scheduled 3 months after the Final Study/Treatment Discontinuation Visit.

Time frame:
From enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment
Reported as:
Median · Month
Progression Free Survival (PFS)
MonthTreatment With or Without Biopsy
Progression Free Survival (PFS)3.75 (2.37 to NA)
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the time from enrollment to death from any cause. Patients without a documented death were censored at their off-study date. Per protocol, patients were followed until death, withdrawal of consent, loss to follow-up, or study termination. Survival follow-up was scheduled every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit. The study was terminated before participants reached the first prespecified survival follow-up assessment, scheduled 3 months after the Final Study/Treatment Discontinuation Visit.

Time frame:
From enrollment until death from any cause, withdrawal of consent, loss to follow-up, or study termination, with survival follow-up every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit, per protocol.
Reported as:
Median · Month
Overall Survival (OS)
MonthTreatment With or Without Biopsy
Overall Survival (OS)NA (NA to NA)

Adverse events

Collected over Data on adverse events were collected from the time of enrollment until 30 days after the final dose of study treatment, until study discontinuation/termination, or until the initiation of new systemic anti-cancer therapy, whichever occurred first, up to 5 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Enrolled Patients1/13 (7.7%)7/13 (53.8%)12/13 (92.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAll Enrolled Patients
Abdominal painGastrointestinal disorders2/13
AscitesGastrointestinal disorders1/13
DiarrheaGastrointestinal disorders1/13
Disease progressionGeneral disorders and administration site conditions1/13
Failure to thriveGeneral disorders and administration site conditions1/13
FeverGeneral disorders and administration site conditions1/13
Hepatic hemorrhageHepatobiliary disorders1/13
Skin infectionInfections and infestations1/13
Hepatic event- elevated lftsInvestigations1/13
HyperbilirubinemiaInvestigations1/13
Most frequent other events
Showing 10 of 40
Most frequent other events
EventAll Enrolled Patients
HeadacheNervous system disorders4/13
HypertensionVascular disorders3/13
ConstipationGastrointestinal disorders2/13
DiarrheaGastrointestinal disorders2/13
NauseaGastrointestinal disorders2/13
FatigueGeneral disorders and administration site conditions2/13
Alanine aminotransferase increasedInvestigations2/13
Aspartate aminotransferase increasedInvestigations2/13
ThrombocytopeniaInvestigations2/13
Febrile neutropeniaBlood and lymphatic system disorders1/13

Baseline characteristics

All 12 patients who were enrolled and received study treatment are included.

Age, Continuous
Age, Continuous(years)Treatment With or Without Biopsy
Median56.5 (51.5 to 65.0)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment With or Without Biopsy
Female5
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment With or Without Biopsy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White11
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment With or Without Biopsy
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Aug 2025, 5 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2025 → Aug 2025 and completion May 2028 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 20, 2025
StartActual
Mar 25, 2025
Primary completionActual
Aug 27, 2025was Sep 2025
CompletionActual
Sep 17, 2025was May 2028
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Drugs unavailable
changed Nov 20, 2026
Results
Results posted
posted Nov 20, 2026
Sites
1 site added, 1 site removed
Show site
  • University of Colorado Hospital · Aurora, United States
Show 1 removed
  • Universtiy of Colorado Hospital · Aurora, United States
Nov 20, 2026
Primary completion
Sep 18, 2025→Aug 27, 2025
Nov 20, 2026
Study completion
May 2028→Sep 17, 2025 (actual)
Nov 20, 2026
Interventions
Removed Procedure: Pre-Treatment Biopsy·Procedure: On-Treatment Biopsy. Arm changed Treatment with Biopsy→Treatment with or without Biopsy. Arms removed: Treatment without Biopsy
Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective Response Rate (ORR) Per RECIST v1.1Time frame: From time of study start to time of best response, up to 24 months → From screening/baseline tumor assessment through the last available tumor assessment, up to 5 months.
Nov 20, 2026
Secondary outcomes
2 time frame changed, 7 removed, 2 description edited
What changed in the outcomes
  • RemovedSafety measured by adverse eventsTime frame: From time of study start until time of study end, up to 24 months
  • RemovedImpact of Liver Metastases on Treatment Response- ORRTime frame: From time of study start to time of best response (ORR), up to 24 months
  • RemovedImpact of Liver Metastases on Treatment Response- PFSTime frame: From time of study start until disease progression or death, whichever comes first; up to 24 months
  • RemovedImpact of Liver Metastases on Treatment Response- OSTime frame: From time of study start until death by any cause, up to 24 months
  • Time frameProgression Free Survival (PFS)From time of study start until disease progression or death, whichever comes first; up to 24 months → From enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment
  • Time frameOverall Survival (OS)From time of study start until death by any cause, up to 24 months → From enrollment until death from any cause, withdrawal of consent, loss to follow-up, or study termination, with survival follow-up every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit, per protocol.
  • DescriptionOverall Survival (OS): how it is measured was reworded
  • DescriptionProgression Free Survival (PFS): how it is measured was reworded
  • Removedother outcomeDisease Control Rate (DCR)Time frame: From time of study start to time of best response, up to 24 months
  • Removedother outcomeDuration of Response (DOR)Time frame: From time of response to treatment through time of progression or death, up to 24 months
  • Removedother outcomeImmune Correlates of ResponseTime frame: Testing will be performed using samples collected prior to the first study treatment and at the time of the third study treatment, approximately 42 days later.
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Active, not recruiting→Terminated
    Why stopped Drugs unavailable
    Results posted
    1 site added, 1 site removed
    Show site
    • University of Colorado Hospital · Aurora, United States
    Show 1 removed
    • Universtiy of Colorado Hospital · Aurora, United States
    Primary completion Sep 18, 2025→Aug 27, 2025
    Study completion May 2028→Sep 17, 2025 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective Response Rate (ORR) Per RECIST v1.1Time frame: From time of study start to time of best response, up to 24 months → From screening/baseline tumor assessment through the last available tumor assessment, up to 5 months.
    Secondary outcomes 2 time frame changed, 7 removed, 2 description edited
    What changed in the outcomes
    • RemovedSafety measured by adverse eventsTime frame: From time of study start until time of study end, up to 24 months
    • RemovedImpact of Liver Metastases on Treatment Response- ORRTime frame: From time of study start to time of best response (ORR), up to 24 months
    • RemovedImpact of Liver Metastases on Treatment Response- PFSTime frame: From time of study start until disease progression or death, whichever comes first; up to 24 months
    • RemovedImpact of Liver Metastases on Treatment Response- OSTime frame: From time of study start until death by any cause, up to 24 months
    • Time frameProgression Free Survival (PFS)From time of study start until disease progression or death, whichever comes first; up to 24 months → From enrollment to the first documented disease progression or death from any cause, whichever occurred first. Patients without documented progression or death were censored at the date of their last adequate disease assessment
    • Time frameOverall Survival (OS)From time of study start until death by any cause, up to 24 months → From enrollment until death from any cause, withdrawal of consent, loss to follow-up, or study termination, with survival follow-up every 3 months (±14 days) after the Final Study/Treatment Discontinuation Visit, per protocol.
    • DescriptionOverall Survival (OS): how it is measured was reworded
    • DescriptionProgression Free Survival (PFS): how it is measured was reworded
    • Removedother outcomeDisease Control Rate (DCR)Time frame: From time of study start to time of best response, up to 24 months
    • Removedother outcomeDuration of Response (DOR)Time frame: From time of response to treatment through time of progression or death, up to 24 months
    • Removedother outcomeImmune Correlates of ResponseTime frame: Testing will be performed using samples collected prior to the first study treatment and at the time of the third study treatment, approximately 42 days later.
    Interventions Removed Procedure: Pre-Treatment Biopsy·Procedure: On-Treatment Biopsy. Arm changed Treatment with Biopsy→Treatment with or without Biopsy. Arms removed: Treatment without Biopsy
    + 4 other changes: index terms, verification date, oversight details and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06784947
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Mar 25, 2025
Primary completion
Aug 27, 2025
Completion
Sep 17, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Hannah Robinson, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tiragolumab · Bevacizumab

Start the discussion